Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

An active learning approach for rapid characterization of endothelial cells in human tumors

  • Raghav K. Padmanabhan
  • , Vinay H. Somasundar
  • , Sandra D. Griffith
  • , Jianliang Zhu
  • , Drew Samoyedny
  • , Kay See Tan
  • , Jiahao Hu
  • , Xuejun Liao
  • , Lawrence Carin
  • , Sam S. Yoon
  • , Keith T. Flaherty
  • , Robert S. DiPaola
  • , Daniel F. Heitjan
  • , Priti Lal
  • , Michael D. Feldman
  • , Badrinath Roysam
  • , William M.F. Lee

Producción científica: Articlerevisión exhaustiva

22 Citas (Scopus)

Resumen

Currently, no available pathological or molecular measures of tumor angiogenesis predict response to antiangiogenic therapies used in clinical practice. Recognizing that tumor endothelial cells (EC) and EC activation and survival signaling are the direct targets of these therapies, we sought to develop an automated platform for quantifying activity of critical signaling pathways and other biological events in EC of patient tumors by histopathology. Computer image analysis of EC in highly heterogeneous human tumors by a statistical classifier trained using examples selected by human experts performed poorly due to subjectivity and selection bias. We hypothesized that the analysis can be optimized by a more active process to aid experts in identifying informative training examples. To test this hypothesis, we incorporated a novel active learning (AL) algorithm into FARSIGHT image analysis software that aids the expert by seeking out informative examples for the operator to label. The resulting FARSIGHT-AL system identified EC with specificity and sensitivity consistently greater than 0.9 and outperformed traditional supervised classification algorithms. The system modeled individual operator preferences and generated reproducible results. Using the results of EC classification, we also quantified proliferation (Ki67) and activity in important signal transduction pathways (MAP kinase, STAT3) in immunostained human clear cell renal cell carcinoma and other tumors. FARSIGHT-AL enables characterization of EC in conventionally preserved human tumors in a more automated process suitable for testing and validating in clinical trials. The results of our study support a unique opportunity for quantifying angiogenesis in a manner that can now be tested for its ability to identify novel predictive and response biomarkers.

Idioma originalEnglish
Número de artículoe90495
PublicaciónPLoS ONE
Volumen9
N.º3
DOI
EstadoPublished - mar 6 2014

Nota bibliográfica

Funding Information:
Multispectral microscopy was performed in the Tumor Tissue and Biosample Bank (TTAB) facility, which is supported by the Department of Pathology & Laboratory Medicine and Abramson Cancer Center (P30 CA16520). We thank Jaromir Pastorek (Slovak Academy of Sciences, Bratislava, Slovak Republic) for M75 anti-CA IX antibody .

Financiación

Multispectral microscopy was performed in the Tumor Tissue and Biosample Bank (TTAB) facility, which is supported by the Department of Pathology & Laboratory Medicine and Abramson Cancer Center (P30 CA16520). We thank Jaromir Pastorek (Slovak Academy of Sciences, Bratislava, Slovak Republic) for M75 anti-CA IX antibody .

FinanciadoresNúmero del financiador
Department of Pathology & Laboratory Medicine and Abramson Cancer CenterP30 CA16520
National Institutes of Health (NIH)T32 CA093283, R01 CA135509
Tumor Tissue and Biosample Bank
National Childhood Cancer Registry – National Cancer InstituteR01CA135509
National Childhood Cancer Registry – National Cancer Institute

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • General

    Huella

    Profundice en los temas de investigación de 'An active learning approach for rapid characterization of endothelial cells in human tumors'. En conjunto forman una huella única.

    Citar esto